Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. (April 2015)

• Record Type: Journal Article
• Authors: Reguart, Noemi; Remon, Jordi
• Is Part Of: Future oncology. Volume 11:Number 8(2015)
• Page Start: 1245
• Page End: 1257
• Publication Date: 2015-04
• Subjects: afatinib -- chemotherapy -- Del19 -- EGFR -- erlotinib -- gefitinib -- L858R -- mutations -- NSCLC -- TKI; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.15
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Ten years ago, somatic mutations in EGFR were identified in patients with non-small-cell lung cancer. Demonstration of the antitumor efficacy of EGF receptor-directed tyrosine kinase inhibitors resulted in their approval for the treatment of advanced non-small-cell lung cancer. Insights into the role of EGFR -sensitizing mutations and acquired and de novo T790M resistance mutations followed, and differences in progression-free survival for patients with EGFR Del19- and L858R-mutated tumors treated with reversible first-generation EGF receptor tyrosine kinase inhibitors were reported. Recently, overall survival benefit in patients with Del19- but not L858R-mutated tumors has been demonstrated after treatment with afatinib, an irreversible ErbB family blocker. Although the biology underlying this difference in survival is currently unclear, this review examines several hypotheses.